{"id":"W2326276419","doi":"10.1158/1557-3125.advbc-a050","title":"Abstract A050: ARRY-380, an oral HER2 inhibitor: Final phase 1 results and conclusions","year":2013,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lapatinib; Medicine; Neratinib; Limiting; Pharmacokinetics; Pharmacology; Adverse effect; Clinical trial; Internal medicine; Oncology; Maximum tolerated dose; Trastuzumab; Breast cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004582152,0.000171881,0.0002751837,0.0002103821,0.000230335,0.00006638884,0.0001217673,0.0001277743,0.002214107],"category_scores_gemma":[0.00006691107,0.0001463486,0.00006432048,0.0003101,0.0003025137,0.0001409367,0.0001355366,0.0005921454,0.0001204401],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002314283,"about_ca_system_score_gemma":0.0004910623,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006650373,"about_ca_topic_score_gemma":0.0004716997,"domain_scores_codex":[0.9979396,0.0001582269,0.0002488922,0.0004850605,0.0005810754,0.0005871006],"domain_scores_gemma":[0.9986914,0.00008460649,0.00004073662,0.000345242,0.0003280616,0.0005099219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002182788,0.001073232,0.001137783,0.00008069968,0.0001584838,0.0008302286,0.0005874261,0.000005898069,0.8768541,0.00007628457,0.05797753,0.05903561],"study_design_scores_gemma":[0.06664723,0.01124009,0.04172885,0.000485113,0.0003464211,0.0002127158,0.0008476221,0.001183916,0.5771496,0.001233596,0.2979833,0.0009416019],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842173,0.002484419,0.000008027693,0.008074458,0.0001433187,0.000997862,0.00008145286,0.00004761133,0.003945572],"genre_scores_gemma":[0.9953732,0.0005828225,0.0001397784,0.0006989571,0.000310463,0.0003886274,0.0001073944,0.00003681968,0.002361952],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2997045,"threshold_uncertainty_score":0.9999644,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1471978799053764,"score_gpt":0.5059109550626726,"score_spread":0.3587130751572961,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}